Posted by Presse
Commercial & Investment Banking, Picture Gallery
Wednesday, July 3rd, 2013
SAN DIEGO, CA — (Marketwired) — 07/03/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive-lipid-targeted therapeutics, today announced that it will participate in the JMP Securities Healthcare Conference in New York, taking place July 9-10, 2013. President and Chief Executive Officer Scott R. Pancoast will give his presentation on Tuesday, July 9, 2013 at 2:30 p.m. EDT (11:30 a.m. PDT). He will discuss the company-s pathway to regulatory approval and commercialization of its no
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Friday, March 22nd, 2013
Patents Provide Coverage for Lpath-s Anti-S1P Antibody in the Treatment of a Wide Variety of Hyperproliferative Disorders, Including Cancer
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Tuesday, March 12th, 2013
SAN DIEGO, CA — (Marketwire) — 03/12/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present at the ROTH Capital Partners 25th Annual Growth Stock Conference being held on March 17-20, 2013, at The Ritz Carlton in Dana Point, Calif.Lpath President and CEO Scott Pancoast is scheduled to present on Tuesday, March 19, 2013 at 1:00 p.m. Pacific time, with one-on-one meetings held throughout the day. He will discuss the company-s
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Wednesday, March 6th, 2013
SAN DIEGO, CA — (Marketwire) — 03/06/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has signed a collaboration and license agreement to develop cancer diagnostics with Provista Diagnostics, Inc. a leader in molecular cancer diagnostics and a CLIA-accredited reference laboratory.The collaboration will focus on the bioactive lipid lysophosphatidic acid (LPA), with the agreement granting Provista an exclusive license to Lpath-s murine LPA antibodi
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Monday, February 25th, 2013
SAN DIEGO, CA — (Marketwire) — 02/25/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has been invited to present data from its Lpathomab program in models of central nervous system injury, including traumatic brain injury (TBI), at Arrowhead-s 3rd Annual Traumatic Brain Injury Conference.Lpathomab is a first-in-class monoclonal antibody that binds to and neutralizes lysophosphatidic acid (LPA), a bioactive lipid that has been implicated in neuro
Posted by Presse
Investment Services & Trading, Picture Gallery
Wednesday, February 13th, 2013
SAN DIEGO, CA — (Marketwire) — 02/13/13 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, has promoted Leigh Hsu, Ph.D., to the new position of vice president of corporate development.Dr. Hsu has more than 13 years of business-development experience in the biotech industry. Prior to joining Lpath in 2008 as its senior director of business development, he held positions of increasing responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Wednesday, December 26th, 2012
SAN DIEGO, CA — (Marketwire) — 12/26/12 — Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, will hold a conference call on Thursday, January 3, 2013 at 4:30 p.m. Eastern time to provide an update on its Nexus Phase 2 trial for iSONEP, an ocular drug candidate, as well as outline the company-s 2013 objectives.Lpath President and CEO Scott Pancoast will host the presentation, followed by a question-and-answer period.Date: Thursday, January 3, 2013
Time:
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Friday, December 14th, 2012
SAN DIEGO, CA — (Marketwire) — 12/14/12 — Lpath, Inc. (NASDAQ: LPTN), today announced that it is selling 2,366,000 shares of its common stock at a price to the public of $5.00 per share. The gross proceeds from the sale of the shares, before deducting the underwriting discount and estimated offering expenses payable by it, are expected to be approximately $11.8 million.Lpath intends to use the net proceeds from this offering for research and development activities, operating costs, capital e
Posted by Presse
Investment Services & Trading, Picture Gallery
Thursday, December 13th, 2012
SAN DIEGO, CA — (Marketwire) — 12/13/12 — Lpath, Inc. (NASDAQ: LPTN) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be complete, or as to the actual size or terms of the offering. Summer Street Research Partners is acting as sole book-running manager for the offering.The securities described above are being offered
Posted by Presse
Commercial & Investment Banking, Picture Gallery
Wednesday, December 5th, 2012
New Patent Provides Coverage for Lpath-s Anti-S1P Antibody, Sonepcizumab, in the Treatment of a Wide Variety of Ocular Disorders
